ARCHIVES

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

On Capitol Hill: Cancer Organizations Push Congress For Payment Of Patient Care Costs In Trials

September 17, 1999

Pre-Emptive Treatment Helped Curtail Panitumumab Toxicity

January 30, 2009

In Brief: House Cuts NCI Rescission To $7.73 Million; Weinhuse, Ultmann New ACCR, ASCO Presidents

May 8, 1981

In Congress: NCI Defends Role of Advisor In Response To House Inquiry

September 19, 1997

One Year Later, Cancer Centers And NCI are Getting Along Just Fine, AACI Learns

July 27, 1990

In Brief: Duke’s Gary Lyman to Co-Direct Fred Hutch Outcomes Research

January 10, 2014